文献速递系统性红斑狼疮

阿尼鲁单抗在系统性红斑狼疮患者中按I型干扰素基因特征及临床亚组的疗效与安全性:两项III期试验汇总数据的事后分析

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.
PubMed 文献 · Ann Rheum Dis · 2022-03-25

该事后分析汇总TULIP-1/TULIP-2两项52周III期安慰剂对照试验数据,评估静脉阿尼鲁单抗300 mg在726例中重度SLE患者中按IFNGS及人口学、临床亚组的疗效与安全性。总人群中阿尼鲁单抗组第52周BICLA缓解率较安慰剂组差异为16.6%(名义p<0.001),多数预设亚组治疗差异与总人群相当,IFNGS高、基线血清学异常及亚洲患者亚组差异更大,安全性各亚组相似。

要点

  • 总人群中阿尼鲁单抗组第52周BICLA缓解率较安慰剂组差异为16.6%(名义p<0.001)。
  • 治疗差异较大的亚组包括IFNGS高患者(18.2%)、基线血清学异常患者(23.1%)和亚洲患者(29.2%)。
  • 阿尼鲁单抗安全性在各亚组间相似。

核心结论

  • 总体而言,本研究支持阿尼鲁单抗在广泛的中重度SLE患者中具有一致的疗效和安全性。
  • 在少数亚组中,样本量小限制了关于阿尼鲁单抗治疗获益的结论。

研究设计与样本

  • 对52周III期TULIP-1/TULIP-2安慰剂对照试验汇总数据进行事后分析,评估静脉阿尼鲁单抗在中重度SLE患者中的疗效与安全性。
  • 汇总数据中患者接受阿尼鲁单抗300 mg(360/726)或安慰剂(366/726),82.6%为IFNGS高。

主要发现

  • IFNGS高患者较IFNGS低患者基线疾病活动度更高,且更可能有血清学标志物异常。
  • 总人群中阿尼鲁单抗组较安慰剂组第52周BICLA缓解率差异为16.6%(名义p<0.001)。
  • 多数预设亚组中阿尼鲁单抗较安慰剂的BICLA缓解治疗差异与总人群相当,包括基线糖皮质激素剂量(<10/≥10 mg/天泼尼松/等效)和临床疾病活动度(SLE疾病活动指数2000评分<10/≥10)亚组。
  • 治疗差异较大的亚组包括IFNGS高患者(18.2%)、基线血清学标志物异常患者(23.1%)和亚洲患者(29.2%)。
  • 阿尼鲁单抗的安全性在各亚组间相似。

关键数值与推荐

  • 总人群中阿尼鲁单抗组较安慰剂组第52周BICLA缓解率差异为16.6%(名义p<0.001)。
  • IFNGS高患者亚组BICLA缓解治疗差异为18.2%。
  • 基线血清学标志物异常患者亚组BICLA缓解治疗差异为23.1%。
  • 亚洲患者亚组BICLA缓解治疗差异为29.2%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 在少数亚组中,样本量小限制了关于阿尼鲁单抗治疗获益的结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To characterise the efficacy and safety of anifrolumab in patients with systemic lupus erythematosus (SLE) according to interferon gene signature (IFNGS), demographic and clinical subgroups. METHODS: We performed post hoc analyses of pooled data from the 52-week phase III TULIP-1/TULIP-2 placebo-controlled trials of intravenous anifrolumab in moderate-to-severe SLE. Outcomes were assessed in predefined subgroups: IFNGS (high/low), age, sex, body mass index, race, geographic region, age of onset, glucocorticoid use, disease activity and serological markers. RESULTS: In pooled data, patients received anifrolumab 300 mg (360/726) or placebo (366/726); 82.6% were IFNGS-high. IFNGS-high patients had greater baseline disease activity and were more likely to have abnormal serological markers versus IFNGS-low patients. In the total population, a greater proportion of patients treated with anifrolumab versus placebo achieved British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response at week 52 (difference 16.6%; nominal p<0.001). BICLA response treatment differences with anifrolumab versus placebo were comparable to the total population across most predefined subgroups, including subgroups for baseline glucocorticoid dosage (<10/≥10 mg/day prednisone/equivalent) and for clinical disease activity (SLE Disease Activity Index 2000 score <10/≥10). Subgroups with larger treatment differences included IFNGS-high patients (18.2%), patients with abnormal baseline serological markers (23.1%) and Asian patients (29.2%). The safety profile of anifrolumab was similar across subgroups. CONCLUSIONS: Overall, this study supports the consistent efficacy and safety of anifrolumab across a range of patients with moderate-to-severe SLE. In a few subgroups, small sample sizes limited conclusions from being drawn regarding the treatment benefit with anifrolumab. TRIAL REGISTRATION NUMBER: NCT02446912, NCT02446899.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Vital EM, Merrill JT, Morand EF, et al. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann Rheum Dis. 2022. PMID: 35338035. doi:10.1136/annrheumdis-2021-221425

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。